Magnus Ingelman-Sundberg

Pharmacology · 2001–2016

A researcher in the Science corpus: 8 papers; trusts 3 researchers and is trusted by 15 researchers here, as inferred from the citation graph.

Subfields

• Pharmacology — 47 citations into it; #65 of 1,112 by trust here, #240 by citations
• Oncology — 22 citations into it; #127 of 1,698 by trust here, #923 by citations
• Genetics — 12 citations into it
• Clinical Biochemistry — 5 citations into it

Whom Magnus Ingelman-Sundberg trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Richard M. Weinshilboum
2. William E. Evans
3. S. Sim
4. Ulrich M. Zanger
5. G. Wilkinson
6. Mary V. Relling
7. T. Bestor
8. Barbara E. Stranger
9. M. Eichelbaum
10. David R. Nelson

Who trusts Magnus Ingelman-Sundberg overall

1. Shufeng Zhou
2. M. Eichelbaum
3. Ulrich M. Zanger
4. D. Nebert
5. D. Waxman
6. S. Sim
7. P. Gillman
8. M. Schwab
9. Jun-Ping Liu
10. A. Gomez

Papers from Magnus Ingelman-Sundberg's perspective

Ordered by how strongly the researchers Magnus Ingelman-Sundberg trusts endorse each paper. Same corpus, a different order for every researcher.

1. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response (Molecular Psychiatry)
2. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism (Clinical Pharmacokinetics)
3. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. (TIPS - Trends in Pharmacological Sciences)
4. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity (The Pharmacogenomics Journal)
5. Inheritance and drug response. (New England Journal of Medicine)
6. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression (Nature Genetics)
7. The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution (Science)
8. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. (Proceedings of the National Academy of Sciences of the United States of America)
9. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. (Gastroenterology)
10. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. (Cancer Research)

Their papers

• Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity (2005) — 1,126 citations
• Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease (2016) — 655 citations
• Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007) — 1,166 citations
• Pharmacogenomics and individualized drug therapy. (2006) — 673 citations
• A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (2006) — 778 citations
• Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. (2004) — 671 citations
• Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. (2004) — 992 citations
• Metabolic gene polymorphism frequencies in control populations. (2001) — 921 citations